Refreshed content for NAD+ai_activityai-researcherApr 17, 2026
Pulled 4 linked studies for context.
No external link
Summary not yet generated. The Librarian will pick this up on the next daily run (12:00 UTC).
Community effect votes, structured logs, and side-effect summaries.
Effect profile (overview)
Aggregate AI baseline blended with community voting. Hover to inspect effect strengths per category.
Effect scores blend an AI baseline with community votes. Open the full chart to see sliders and vote on each category.
Research log summary heatmap
Compact view of how logs describe shifts in pain, sleep, and performance (−5 to +5). Treat this as qualitative, anonymous signal only.
No community research logs yet. When structured logs are added, this panel will summarize typical shifts in pain, sleep, and performance.
Anonymous side-effect patterns
Rough heatmap of anonymous side-effect and positive-signal tags — a "most-mentioned" snapshot, not safety or efficacy advice.
No anonymous side-effect reports yet. When reports are submitted, this panel will show a simple heatmap of tags like "nausea", "flushing", "improved healing", and more.
Research footprint
Last analyzed Apr 17, 20268
Studies indexed
0
Human
2
Animal
7
AI analyzed
Evidence mix0% human · 25% animal · 0% cellular · 0% review
Highest phase: PreclinicalYears covered: 2026
Librarian pulse — latest actionsFull changelog ↓
- Apr 17, 12:04 PMRefreshedRefreshed content for NAD+
- Apr 16, 5:14 PMRefreshedRefreshed content for NAD+
- Apr 16, 5:14 PMRefreshedRefreshed content for NAD+
Research & intelligence feed
Studies, clinical trials, community discussions, and news.
Refreshed content for NAD+ai_activityai-researcherApr 16, 2026
Pulled 4 linked studies for context. - **content** added: Body content generated (1385 chars).
No external link
Refreshed content for NAD+ai_activityai-researcherApr 16, 2026
Pulled 4 linked studies for context. - **content** added: Body content generated (1470 chars).
No external link
A Phase 1 Open-label Study of KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid LeukemiaClinical TrialClinicalTrials.govApr 16, 2026
This study evaluated KPT-9274 in patients with relapsed and refractory acute myeloid leukemia (AML). The specific dose and outcomes were not detailed in the abstract. The study's findings are relevant for understanding the potential effects of KPT-9274 in this patient population.
Phase: PHASE1Status: COMPLETED
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Phase 3, Multicenter Trial Investigating the Efficacy and Safety of C21 as add-on to Standard of Care in Adult Subjects With COVID-19Clinical TrialClinicalTrials.govApr 16, 2026
This study investigated the efficacy and safety of C21 as an add-on to standard care in adult subjects with COVID-19. The trial was randomized, double-blind, and placebo-controlled. Not reported in abstract.
Phase: PHASE3Status: COMPLETED
Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent RccClinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the efficacy of adjuvant sunitinib compared to placebo in subjects at high risk of recurrent renal cell carcinoma (RCC). The trial was a randomized double-blind phase 3 study. Not reported in abstract.
Phase: PHASE3Status: COMPLETED
An Open-Label, Multi-Center Extension Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects With Moderate-to-Severe Plaque PsoriasisClinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the long-term safety and efficacy of BMS-986165 in subjects with moderate-to-severe plaque psoriasis. The specifics regarding the dosage and duration of treatment were not reported in the abstract. The findings related to efficacy and safety are crucial for understanding the potential long-term implications of this treatment.
Phase: PHASE3Status: ACTIVE_NOT_RECRUITING
An Open-label, Single Arm, Roll-over Study to Provide Continued Treatment With Darolutamide in Participants Who Were Enrolled in Previous Bayer Sponsored StudiesClinical TrialClinicalTrials.govApr 16, 2026
This study evaluated the continued treatment with Darolutamide in participants previously enrolled in Bayer-sponsored studies. The specific outcomes measured and the population characteristics are not detailed in the abstract. The study was conducted as an open-label, single-arm trial.
Phase: PHASE3Status: ACTIVE_NOT_RECRUITING
Semantic Scholar search for NAD+StudySemanticScholarDec 12, 2025
Single-cell analysis integrated with RNA-Sequencing uncovers new action of Patchoulol on adipose tissue remodeling in obesity.StudyPubMedDec 12, 2025
Not reported in abstract.
Nicotinamide riboside enhances the efficacy of gemcitabine and suppresses PDAC premalignant lesions via SIRT3 activation.StudyPubMedDec 12, 2025
Not reported in abstract.
SMP30 May protect human lens epithelial cells against high glucose-induced oxidative damage by regulating the Keap1/Nrf2/NQO1 pathway.StudyPubMedDec 12, 2025
Not reported in abstract.
External databases
Helpful external resources for additional structural, pharmacologic, and literature context. These are third-party databases; always cross-check details with primary research.
Community notes
No comments yet. Share research notes, citations, or observations below.
Community research logs (detail)
No community research logs yet. Use the “Contribute data” button above to share an anonymized summary of your experience.
Anonymous side-effect reporting (detail)
This section describes how anonymous side-effect reports are aggregated into the heatmap above. Reports are anonymous and unverified, and should be read alongside primary safety data.
Use the "Report side effects" button to open a focused popup form. Please keep descriptions neutral and avoid medical language; think in terms of "nausea", "flushing", "vivid dreams", etc.
Librarian Changelog
Every time the Librarian touches this peptide — discovering, refreshing, scoring, or verifying — it logs the action here.
22h agoRefreshai-researcher85%
Refreshed content for NAD+
1d agoRefreshai-researcher85%
Refreshed content for NAD+
1d agoRefreshai-researcher85%
Refreshed content for NAD+